Gyre Therapeutics (GYRE) Stock: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$5.86
-0.04 (-0.68%)
▼
5d:
-8.44%
30d:
-20.81%
90d:
-1.35%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 06, 2026
13d
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GYRE shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GYRE shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $5.86, which is considered oversold relative to its 30-day fair value range of $6.39 to $7.40. From a valuation perspective, the stock is trading at a discount (Forward PE: -24.9) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a uptrend. The price is currently testing key support at $5.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.67 (+218.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GYRE is in a uptrend. The price is currently testing key support at $5.80. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.67 (+218.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.39 -
$7.40
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 218.5% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.39 -
$7.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.80
Resistance Level
$7.09
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.94
Wall Street Target
$18.67
(+218.5%)
Revenue Growth (YoY)
-2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-19.3%
PE vs Historical
-24.9 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: October 22, 2026 9:09 PM ET
Data refreshes hourly during market hours. Next update: 10:09 PM
Data refreshes hourly during market hours. Next update: 10:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
